Prokidney reports fourth quarter financial results and recent corporate highlights

Winston-salem, n.c., march 28, 2023 (globe newswire) -- prokidney corp. (nasdaq: prok) (“prokidney” or the “company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (ckd), today announced financial results for the fourth quarter ended december 31, 2022, and provided an update on recent corporate developments.
PROK Ratings Summary
PROK Quant Ranking